ERBB2 and breast cancer: An ongoing phase I clinical trial, PALVEN (NCT03900884) [137] is evaluating the safety and efficacy of AI plus CDK4/6is plus venetoclax triple therapy as a first-line treatment for patients with ER+/HER2− advanced BC with BCL2 overexpression, and we are waiting for the results.